

JAN 07 2004

PTO/SB/08A (10/01) (modified)  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

SUBSTITUTE for form 1449A/PTO

INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

3

of

7

Application Number

10/631,029

Filing Date

July 29, 2003

First Name of Inventor

Rajinder Singh

Art Unit

Unknown

Examiner Name

Unknown

Attorney Docket Number

28575/US/US

## FOREIGN PATENT DOCUMENTS

Examiner Initials	Cite No.	FOREIGN PATENT DOCUMENT	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	TRANSLATION
Re		WO 03/018021	3/6/2003	Amgen Inc.	<input type="checkbox"/> <input checked="" type="checkbox"/>	<input type="checkbox"/> <input checked="" type="checkbox"/>
		WO 03/016306	2/27/2002	Janssen Pharmaceutica N.V.	<input type="checkbox"/> <input checked="" type="checkbox"/>	<input type="checkbox"/> <input checked="" type="checkbox"/>
		WO 03/002544	1/9/2003 2/10/03	Bristol-Myers Squibb Company	<input type="checkbox"/> <input checked="" type="checkbox"/>	<input type="checkbox"/> <input checked="" type="checkbox"/>
		WO 03/000186	1/3/2003	Ariad Pharmaceuticals Inc.	<input type="checkbox"/> <input checked="" type="checkbox"/>	<input type="checkbox"/> <input checked="" type="checkbox"/>
		WO 02/102313	12/27/2002	Bristol-Myers Squibb Company	<input type="checkbox"/> <input checked="" type="checkbox"/>	<input type="checkbox"/> <input checked="" type="checkbox"/>
		WO 02/066481	8/29/2002	Astrazeneca AB	<input type="checkbox"/> <input checked="" type="checkbox"/>	<input type="checkbox"/> <input checked="" type="checkbox"/>
		WO 02/066480	8/29/2002	Astrazeneca AB	<input type="checkbox"/> <input checked="" type="checkbox"/>	<input type="checkbox"/> <input checked="" type="checkbox"/>
		WO 02/066461	8/28/2002	Vertex Pharmaceuticals, Inc.	<input type="checkbox"/> <input checked="" type="checkbox"/>	<input type="checkbox"/> <input checked="" type="checkbox"/>
		WO 02/064096	8/22/2002	Tularik Inc.	<input type="checkbox"/> <input checked="" type="checkbox"/>	<input type="checkbox"/> <input checked="" type="checkbox"/>
		WO 02/062789	8/15/2002	Vertex Pharmaceuticals, Inc.	<input type="checkbox"/> <input checked="" type="checkbox"/>	<input type="checkbox"/> <input checked="" type="checkbox"/>
		WO 02/059112	8/1/2002	Vertex Pharmaceuticals, Inc.	<input type="checkbox"/> <input checked="" type="checkbox"/>	<input type="checkbox"/> <input checked="" type="checkbox"/>
		WO 02/059110	8/1/2002	Gilox Group Limited	<input type="checkbox"/> <input checked="" type="checkbox"/>	<input type="checkbox"/> <input checked="" type="checkbox"/>
		WO 02/50066	6/27/2002	Vertex Pharmaceuticals, Inc.	<input type="checkbox"/> <input checked="" type="checkbox"/>	<input type="checkbox"/> <input checked="" type="checkbox"/>
		WO 02/45652	6/13/2002	Merck & Co. Inc.	<input type="checkbox"/> <input checked="" type="checkbox"/>	<input type="checkbox"/> <input checked="" type="checkbox"/>
		WO 02/22601	3/21/2002	Vertex Pharmaceuticals, Inc.	<input type="checkbox"/> <input checked="" type="checkbox"/>	<input type="checkbox"/> <input checked="" type="checkbox"/>
		WO 02/04429	1/17/2002	Astrazeneca AB	<input type="checkbox"/> <input checked="" type="checkbox"/>	<input type="checkbox"/> <input checked="" type="checkbox"/>
		WO 01/85700	11/15/2001	Janssen Pharmaceutica N.V.	<input type="checkbox"/> <input checked="" type="checkbox"/>	<input type="checkbox"/> <input checked="" type="checkbox"/>
		WO 01/85699	11/15/2001	Janssen Pharmaceutica N.V.	<input type="checkbox"/> <input checked="" type="checkbox"/>	<input type="checkbox"/> <input checked="" type="checkbox"/>
		WO 01/72744	10/4/2001	Schering Aktiengesellschaft	<input type="checkbox"/> <input checked="" type="checkbox"/>	<input type="checkbox"/> <input checked="" type="checkbox"/>
		WO 01/64656	9/7/2001	Astrazeneca AB	<input type="checkbox"/> <input checked="" type="checkbox"/>	<input type="checkbox"/> <input checked="" type="checkbox"/>
		WO 01/64654	9/7/2001	Astrazeneca AB	<input type="checkbox"/> <input checked="" type="checkbox"/>	<input type="checkbox"/> <input checked="" type="checkbox"/>
		WO 01/64655	9/7/2001	Astrazeneca UK Limited	<input type="checkbox"/> <input checked="" type="checkbox"/>	<input type="checkbox"/> <input checked="" type="checkbox"/>
Re		WO 00/63182	10/00	4/20/1999 Bayer Aktiengesellschaft	<input type="checkbox"/> <input checked="" type="checkbox"/>	<input type="checkbox"/> <input checked="" type="checkbox"/>


EXAMINER SIGNATURE

Re

DATE CONSIDERED

8-18-05

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



Substitute Form 1449A/PTO				Application Number	10/631,029
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(use as many sheets as necessary)</i>				Filing Date	July 29, 2003
				First Name of Inventor	Rajinder Singh
				Art Unit	Unknown
				Examiner Name	Unknown
Sheet	2	of	7	Attorney Docket Number	28575/US/US

**U.S. PATENT DOCUMENTS**

*Examiner Initials	Cite No.	DOCUMENT NUMBER Number - Kind Code (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
10		US- 5,420,129	5/30/1995	Breu	
		US- 5,223,505	6/29/1993	Hargreaves	
		US- 5,179,204	1/12/1993	Effland et al.	
		US- 5,147,876	9/15/1992	Mizuchi et al.	
		US- 4,983,608	1/8/1991	Effland et al.	
10		US- 3,159,547	12/1/1964	Hollis et al.	

**FOREIGN PATENT DOCUMENTS**


*Examiner Initials	Cite No.	FOREIGN PATENT DOCUMENT		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	TRANSLATION	
		Country Code:	Number - Kind Code (if known)				YES	NO
16		WO	03/078404	9/25/2003	Novartis Pharma GmbH		<input type="checkbox"/>	<input type="checkbox"/>
		WO	03/074515	9/12/2003	Smithkline Beecham Corporation		<input type="checkbox"/>	<input type="checkbox"/>
		WO	03/066601 8/03	3/8/2002	Smithkline Beecham Corporation		<input type="checkbox"/>	<input type="checkbox"/>
		WO	03/062225	7/31/2003	Bayer Corporation		<input type="checkbox"/>	<input type="checkbox"/>
		WO	03/063794	8/7/2003	Rigel Pharmaceuticals Inc.		<input type="checkbox"/>	<input type="checkbox"/>
		WO	03/048133	6/12/2003	Astrazeneca AB		<input type="checkbox"/>	<input type="checkbox"/>
		WO	03/040141	5/15/2003	Bayer Corporation		<input type="checkbox"/>	<input type="checkbox"/>
		WO	03/032997	4/24/2003	Boehringer Ingelheim Pharma KG		<input type="checkbox"/>	<input checked="" type="checkbox"/>
		WO	03/032994	4/24/2003	Boehringer Ingelheim Pharma KG		<input type="checkbox"/>	<input checked="" type="checkbox"/>
		WO	03/030909	4/17/2003	Bayer Corporation		<input type="checkbox"/>	<input type="checkbox"/>
		WO	03/026666	4/3/2003	Bayer Corporation		<input type="checkbox"/>	<input type="checkbox"/>
		WO	03/026665	4/3/2003	Bayer Corporation		<input type="checkbox"/>	<input type="checkbox"/>
		WO	03/026664	4/3/2003	Bayer Corporation		<input type="checkbox"/>	<input type="checkbox"/>
16		WO	03/018022	3/6/2003	Amgen Inc.		<input type="checkbox"/>	<input type="checkbox"/>

EXAMINER SIGNATURE vb

DATE CONSIDERED 8-18-05

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for form 1449A/PTO (Modified) <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (use as many sheets as necessary)				<b>Complete If Known</b>	
Sheet	1	of	1	Application Number	10/631029
				Filing Date	July 29, 2003
				First Named Inventor	Rajinder SINGH
				Art Unit	1614
				Examiner Name	K. WEDDINGTON
				Attorney Docket Number	375462-012US (355218)



<b>U.S. PATENT DOCUMENTS</b>					
Examiner Initials*	Cit No.	Document Number Number-Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	A1	10/355,543 (US 20040029902)	02-12-2004	Singh, et al.	Singh, et al.
	A2	10/858,343 (US 20050038243)	02-17-2005		
	A3	11/299,207	NOT AVAILABLE		
	A4	10/911,684 (US 20050209230)	09-22-2005	Singh, et al.	Singh, et al.
	A5	11/148,746 (US 20060035916)	02-16-2006	Singh, et al.	Singh, et al.
	A6	11/149,105 (US 20060025410)	02-06-2006	Singh, et al.	Singh, et al.
	A7	11/149,418	NOT AVAILABLE		
	A8	10/903,263 (US 20050234049)	10-20-2005	Singh, et al.	Singh, et al.
	A9	10/903,870 (US 20050209224)	09-22-2005	Singh, et al.	Singh, et al.
	A10	11/016,403 (US 20050192301)	09-01-2005		
	A11	10/913,270 (US 20050113398)	05-26-2005	Argade, et al.	Argade, et al.
	A12	11/286,238	NOT Available		
	A13	11/133,419 (US 20060035891)	02-16-06	Li, et al.	Li, et al.
	A14	11/216,532	NOT Available		
	A15	11/280,066	NOT Available		
	A16				
	A17				
	A18				

<b>FOREIGN PATENT DOCUMENTS</b>					
Examiner Initials*	Cit No.	Foreign Patent Document Country Code <sup>2</sup> Number <sup>3</sup> Kind Code <sup>4</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	B1				

<b>NON PATENT LITERATURE DOCUMENTS</b>					
Examiner Initials*	Cit No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and country where published.			
	C1				
	C2				

Examiner Signature	12/27/06	Date Considered	9/26/06	12419946.1.BUSINESS
--------------------	----------	-----------------	---------	---------------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 801.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 18 if possible. <sup>6</sup> Applicant is to place a check mark here if English Language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the complete application form to the USPTO. Time will vary depending on the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing this form, call 1-800-PTO-9199 (1-800-786-9199) and selection option 2